Rabies

This phase 3 trial is testing whether simpler vaccination schedules for rabies are as effective as the standard 5-dose regimen. About 3,000 healthy people aged 10 to 60 will receive the vaccine in different patterns, including fewer total doses. Researchers will measure immune re…

This study tests a new rabies vaccine called ChAdOx2 RabG, given as a single shot. It involves 174 healthy adults (18-45 years) and young children (2-6 years) in a country where rabies is common. The goal is to see if the vaccine is safe and triggers a strong immune response, com…

This study looks at whether a new antibody injection, called zamerovimab and mazorelvimab, combined with the standard rabies vaccine, can prevent rabies in people who have been severely bitten by a dog. The trial follows 80 adults in China for up to one year to see if they stay r…

This study tests a new rabies vaccine in 3,000 healthy people aged 10 to 60. The goal is to see how well it triggers the body's defenses and if it's safe. The vaccine is given in different schedules to find the best way to prevent rabies after a possible exposure.

This early-stage trial is testing the safety of a freeze-dried human rabies vaccine in 80 healthy people aged 10 to 60. Participants receive the vaccine in different schedules, and researchers monitor for side effects for 30 days after the last dose. The goal is to see if the vac…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…